: iStockAnalyst.com Symbols Feed

EXACT Sciences (NASDAQ: EXAS): Patience Required For Long-Term Upside

Thu, 05 Nov 2009 01:21:28 GMT

On 11/3/09, EXACT Sciences (NASDAQ: EXAS) reported its 3Q09 results and held a conference call to outline the Company's progress and timeline for the development of a stool DNA based test kit for the early diagnosis and prevention of colorectal cancer (CRC). EXAS reported total revenue of $1.3 million (which primarily reflects non-cash recognition of Genzyme deal earlier this year), a net loss of $1 million, operating expenses of $2.3 million, and ended the quarter with cash / equivalents of $26.9 million.[More...]

Get Instant Biotech Diversification

Thu, 22 Oct 2009 17:04:36 GMT

Biotechnology is a notoriously volatile industry. Shares of individual firms often skyrocket or plummet based on clinical test results. Because biotechs tend to march to the beat of their own drum--share prices are much more sensitive to clinical trial results and merger activity within the sector than they are to the economic backdrop—they can be an interesting small addition to a satellite portfolio.[More...]

10 Health-Care Stocks To Consider Buying Now

Mon, 28 Sep 2009 13:38:54 GMT

Our Ultimate Stock-Pickers continue to load up on health-care stocks.[More...]

BioMed News Bytes: Dendreon, Chelsea, Cytori, Cephalon, OraSure, Genzyme, Lixte

Thu, 24 Sep 2009 23:01:08 GMT

On 4/28/09, Dendreon (NASDAQ: DNDN) announced that its experimental cancer vaccine Provenge extended the life of patients with advanced prostate cancer by a median of 4.1 months, which is one month longer than the only other treatment option, Taxotere.[More...]

Clolar Gets Cool Reception From FDA And Up For Approval (GENZ, VION)

Wed, 02 Sep 2009 16:04:40 GMT

Genzyme Corporation (Nasdaq:GENZ) has a new drug application for their new drug Clofarabine ( Clolar), a leukemia drug that will be used to treat older patients.[More...]

Genzyme (NASDAQ: GENZ): Upgraded TOutperform At Leerink Swann

Fri, 21 Aug 2009 12:14:29 GMT

My favourite call this morning comes from Leerink Swann. They are upgrading Genzyme (NASDAQ:GENZ) to Outperform from Market Perform based on: 1) MEDACorp consultants' ("consultants") perspective that Vesivirus is unlikely to recur in Allston; and 2) while Gaucher's experts note an eagerness to switch a majority of their patients to Shire's velaglucerase and a reluctance to switch to PLX's prGCD given immunogenicity concerns, the firm does not believe competitors have sufficient capacity at the current time to absorb more than 20% of the population. Leerink believes Street concerns on the Allston manufacturing facility have overshot the mark. Based on: 1) consultants’ feedback that the probability of Vesivirus recurrence is <10%;[More...]

Another Blow For Genzyme (GENZ)

Tue, 18 Aug 2009 18:47:14 GMT

Genzyme Corp. (GENZ) suffered yet another setback yesterday when Protalix BioTherapeutics Inc. announced that the US Food and Drug Administration (FDA) has approved the treatment protocol for its experimental drug for Gaucher disease. This means that the drug, prGCD, will be available for the treatment of Gaucher patients prior to its commercialization. The FDA had approached both Protalix and Shire Plc (SHPGY) last month to consider submitting a treatment protocol that would allow the use of their Gaucher disease treatments under an expanded access program in order to make up for a shortage in the supply of Cerezyme, which is the leading treatment for Gaucher. As a reminder, Genzyme has been[More...]

Safe(r) Ways To Play Biotech

Tue, 18 Aug 2009 13:52:00 GMT

I recently highlighted a small biotech firm, ISIS Pharmaceuticals, as a potential “value” growth play. ISIS took a tumble after earnings despite being just a penny off of estimates. Despite slightly lower than expected earnings, the Company showed a strong cash position, moderate cash burn, and a likelihood that it would be able to at least make it through full trials for its most promising drug. I know that for some even this doesn’t count as value. Afterall, the Company is not free cash positive and any value ascribed to the Company is derived from future expectations of its drug pipeline of which there are none currently in distribution. For those looking for more proven business models but still looking to take advantage of the coming shift towards genetic pharmaceuticals as[More...]

Biggest Declines Among S&P

Tue, 11 Aug 2009 21:05:02 GMT

The following is a list of the S&P 500 firms where the analysts have been cutting their expectations for the current fiscal year the most over the last month. Most likely these firms reported disappointing earnings or gave negative guidance on their conference calls. Historically, you have not wanted to be invested in companies where the analysts who follow them most closely see the earnings prospects diminishing. Also, estimates in motion tend to remain in motion. The first bit of bad news is rarely the last (the cockroach theory). This means that the current expectations, even though down from last month, are probably still to high for these firms. To weed out anomalies, only those firms that are currently expected to earn more than $0.50 in 2009 are included and only those firms where there are a minimum of three estimates in the system. If you have these stocks in your portfolio, you might want to reconsider[More...]

FDA Calendar Updates: Orexo, Novo Nordisk, King, Isis, Facet

Mon, 10 Aug 2009 13:56:00 GMT

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 294 entries as of 8/6/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, ANDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete (...)[More...]

Strategist Offers Investing Tips

Tue, 03 Nov 2009 14:50:00 GMT

Nov. 3--Readers of The News Tribune first met Bruce McCain a year ago when he visited Tacoma to speak with a group of selected high-net-worth clients of Key Private Bank -- where McCain serves as chief investment strategist.
He has earned a doctorate in business administration from the University of California, Berkeley, and is a Certified Financial Analyst.
Alongside speaking with clients and managing portfolios, McCain also appears regularly both in print and broadcast media.

: iStockAnalyst.com Symbols Feed

EXACT Sciences (NASDAQ: EXAS): Patience Required For Long-Term Upside

Get Instant Biotech Diversification

10 Health-Care Stocks To Consider Buying Now

BioMed News Bytes: Dendreon, Chelsea, Cytori, Cephalon, OraSure, Genzyme, Lixte

Clolar Gets Cool Reception From FDA And Up For Approval (GENZ, VION)

Genzyme (NASDAQ: GENZ): Upgraded TOutperform At Leerink Swann

Another Blow For Genzyme (GENZ)

Safe(r) Ways To Play Biotech

Biggest Declines Among S&P

FDA Calendar Updates: Orexo, Novo Nordisk, King, Isis, Facet

Strategist Offers Investing Tips

Ann Taylor, Smucker, Genzyme are big movers

Drug maker begins cleanup to kill virus

Virus pushes drug maker to halt production

Genzyme halts drug production amid scare

Genzyme, Bayer HealthCare Sign New Strategic Agreement

Genzyme Receives FDA Approval to Market Synvisc-One

Scots Company's Radar Invisible Turbines to Expand Wind Industry Special Polymer Means Wind Farms Could Be Built Near Flight Paths Special Polymer Means Wind Farms Could Be Built Near Flight Paths ENERGY: INVENTION

India Economic Summit Closes With Warning of Falling Growth, "but No Crisis"

Unions Blast Biotech Grant ; Say Genzyme Not Paying Fair Wages

Dyadic International Reports Financial Results for First and Second Quarters of 2009 and Fiscal Years 2008 and 2007

Genzyme Reports Third-Quarter Financial Results

Windhover Brings Roche, Genentech Executives Together to Talk Business Development

Genzyme Named to Dow Jones Sustainability World and North American Indexes

Holzer Holzer & Fistel, LLC Announces That a Class Action Lawsuit Has Been Filed on Behalf of Investors in Genzyme Corp.

BenchmarkJournal.Com Free Analyst Review for ENER, GENZ, DLTR, IDTI, COST and EGLE

StockPreacher.com Issues Trading Outlook for Nabi Biopharmaceuticals

Exact Sciences Reports Second-Quarter 2009 Financial Results

Genzyme Provides Update on Cerezyme Supply and 2009 Financial Information

StockPreacher.Com Issues Trading Outlook for Keryx Biopharmaceuticals Inc.

Form 4 GENZYME CORP For: Nov 03 Filed by: COONEY CHARLES L (10K)

Form 4 BERTHIAUME DOUGLAS A For: Sep 30 (10K)

Form 4 DZAU VICTOR J For: Sep 30 (10K)

Form 4 DZAU VICTOR J For: Sep 10 (10K)

Form 4/A GENZYME CORP For: May 21 Filed by: SYRON RICHARD F/CA (10K)

Form 4/A GENZYME CORP For: May 22 Filed by: COONEY CHARLES L (10K)

Form 4/A GENZYME CORP For: May 21 Filed by: CARPENTER ROBERT J (10K)

Form 4/A BOUDREAUX GAIL For: May 21 (10K)

Form 4/A DZAU VICTOR J For: May 21 (10K)

Form 4/A MCGILLICUDY CORNELIUS For: May 21 (10K)